WNT11

Across TCGA pan-cancer cohorts, WNT11 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated WNT11 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher WNT11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated WNT11 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where WNT11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	1.000	0.109	.024	12	view →
LUAD	DFS	Median	II,III,IV	0.718	0.233	.028	2	view →
LSCC	OS	Median	All	0.739	1.000	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

WNT11–CCRCC (DFS)

Open the CCRCC breakdown →